Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY.
Usman BaberRishi ChandiramaniShamir R MehtaSamantha SartoriZhongjie ZhangBimmer E ClaessenCarlo BriguoriSamin K SharmaGeorge D DangasRoxana MehranPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
The safety and efficacy profile of the SYNERGY BP-DES is comparable to that of contemporary DP-DES in high-risk patients undergoing PCI. Compared to ticagrelor plus aspirin, the effect of ticagrelor monotherapy is consistent among patients receiving SYNERGY BP-DES or DP-DES.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- patients undergoing
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- low dose
- clinical trial
- cardiovascular events
- emergency department
- combination therapy
- randomized controlled trial
- type diabetes
- cardiovascular disease
- study protocol
- adverse drug